Topic Hub

Evolocumab — Off-Label Uses

3 clinically reviewed articles, written and peer-reviewed by the HealthRX Medical Team.

3articles

25keywords mapped

2026-05-26latest review

Explore

Evolocumab — Off-Label Uses library

Showing 3 of 3 clinical reviews.

Dosing & Monitoring2026-05-26

Repatha (Evolocumab) for ASCVD Secondary Prevention: Dosing Protocol and Evidence

Evolocumab (Repatha) carries an FDA-approved indication for reducing cardiovascular events in established ASCVD. Learn the dosing protocol, FOURIER trial evidence, guideline recommendations, and when prescribing may extend beyond the label.

Read clinical review

Clinical Reviews2026-05-26

Repatha (Evolocumab) for ASCVD Secondary Prevention: Evidence Summary

A clinical evidence summary of evolocumab (Repatha) for secondary prevention in atherosclerotic cardiovascular disease (ASCVD), including FOURIER trial data, guideline recommendations, dosing, and safety.

Read clinical review

Dosing & Monitoring2026-05-26

Repatha (Evolocumab) for Familial Hypercholesterolemia: Monitoring, Evidence, and Clinical Use

Evolocumab (Repatha) is FDA-approved for heterozygous and homozygous familial hypercholesterolemia. Learn about dosing, monitoring protocols, trial data from FOURIER and RUTHERFORD-2, and guideline recommendations.

Read clinical review